MD of Brigham and Women's Hospital
IPF is a progressive and often fatal lung disease characterized by scarring of the lung tissue, eventually robbing patients of their ability to breathe. About 40,000 people will die from IPF this year, the same number as from breast cancer. An estimated 128,000 people in the United States have IPF, and 48,000 new cases are diagnosed each year. There is currently no FDA-approved treatment for IPF, no cure, and two-thirds of patients die within five years of diagnosis.
A recent study conducted by the Coalition for Pulmonary Fibrosis* found IPF awareness is alarmingly low -- less than one-third of Americans polled had heard of IPF, while 88 percent were aware of cystic fibrosis, and 85 percent knew of ALS, or Lou Gehrig's Disease. IPF is several times more common than cystic fibrosis and ALS, yet it receives a fraction of the research funding.
* Respiratory Medicine: Volume 101, Issue 6, June 2007, Pages 1350-1354 Patient experiences with pulmonary fibrosis Collard, Tino, Noble, Shreve, Michaels, Carlson, Schwarz. (http://www.coalitionforpf.org/ofs/pdf/BRQRespiratoryMedicinePaper.pdf)
The Coalition for Pulmonary Fibrosis (CPF) is a 501(c)(3) nonprofit organization, founded in 2001 to accelerate research efforts leading to a cure for pulmonary fibrosis, while educating, supporting, and advocating for the community of patients, families, and medical professionals fighting this disease. The CPF's nonprofit partners include many of the most respected medical centers and healthcare organizations in the U.S. For more information, visit http://www.coalitionforpf.org.
Beth Israel Deaconess Medical Center is a patient care, teaching and
|SOURCE Coalition for Pulmonary Fibrosis|
Copyright©2008 PR Newswire.
All rights reserved